– Reported Q3 and nine-month revenues of $7.3 million and $21.2 million respectively, up 42% and 66% year-over-year – Provided 2025 guidance with expectations of over 50% annual sales growth, 20%+ reduction in operating expenses, positive full-year EBITDA, and positive cash flow in H2 2025 –
DENVER --(BUSINESS WIRE)--Nov. 11, 2024-- TriSalus Life Sciences ® Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), an oncology company dedicated to enhancing outcomes for patients suffering from liver cancer through its advanced delivery technology as well as an investigational immunotherapy,
DENVER --(BUSINESS WIRE)--Nov. 7, 2024-- TriSalus Life Sciences ® Inc. ("TriSalus" or the "Company") (Nasdaq: TLSI), a leader in oncology innovations integrating advanced delivery technology to transform treatment for liver and pancreatic tumors, today announced the launch of the TriNav ® LV
Call Scheduled for Thursday, November 14, 2024 , at 9:00 a.m. ET DENVER --(BUSINESS WIRE)--Oct. 31, 2024-- TriSalus Life Sciences ® Inc. , (Nasdaq: TLSI), an oncology company dedicated to enhancing outcomes for patients with liver and pancreatic cancer through its advanced delivery technology and
DENVER --(BUSINESS WIRE)--Oct. 14, 2024-- TriSalus Life Sciences ® Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), an oncology company dedicated to enhancing outcomes for patients with liver and pancreatic cancer through its advanced delivery technology and novel immunotherapy, nelitolimod,
DENVER --(BUSINESS WIRE)--Sep. 26, 2024-- TriSalus Life Sciences® Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), an oncology company dedicated to enhancing outcomes for patients with liver and pancreatic cancer through its advanced delivery technology and novel immunotherapy, nelitolimod, has
Pressure enabled drug deliver (PEDD) method significantly increased penetration of glass microspheres into porcine liver tumors (117%; p=0.004 and 39%; p=0.032) with lobar infusions and selective infusions, respectively DENVER --(BUSINESS WIRE)--Sep. 23, 2024-- TriSalus Life Sciences®, Inc.
Reported revenues of $7.4 million in Q2 2024 and $13.8 million for six months ended June 30, 2024 , up 60% and 82%, respectively, compared to prior year periods Reported gross margin of 88% in Q2 2024 and 86% for the six months ended June 30, 2024 , compared to 83% and 81%, respectively, in the
Call Scheduled for Thursday, August 15, 2024 , at 9:00 a.m. ET DENVER --(BUSINESS WIRE)--Aug. 1, 2024-- TriSalus Life Sciences ® Inc. , (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic
WESTMINSTER, Colo. --(BUSINESS WIRE)--Jul. 1, 2024-- TriSalus Life Sciences® Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, announced today the